Dendreon Corp.

Cancer-focused biotech company names Rick Hamm general counsel

Published in Physician Law Weekly, December 15th, 2004

Dendreon Corp. (DNDN) announced the appointment of Rick Hamm as senior vice president and general counsel.

In this new role, Hamm will oversee the company's legal responsibilities including corporate governance, U.S. Securities and Exchange Commission reporting, licensing, and merger and acquisition activity. Hamm will also serve as legal liaison with the appropriate agencies in facilitating the regulatory path forward for Dendreon's investigational lead product, Provenge, a targeted immunotherapy that is currently in a pivotal phase III clinical trial for the treatment of advanced prostate cancer.

Hamm has over 20 years' experience in various legal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry